Cefepime dosing in the morbidly obese patient population

Obesity Surgery

Volumn 22, Issue 3, 2012, Pages 465-471

  Rich, Barrie S ^a   Keel, Rebecca ^c   Ho, Vanessa P ^a   Turbendian, Harma ^a   Afaneh, Cheguevara I ^a   Dakin, Gregory F ^a   Pomp, Alfons ^a   Nicolau, David P ^c   Barie, Philip S ^a,b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c HARTFORD HOSPITAL   (United States)

Author keywords

Antibiotics; Cefepime; Obesity; Pharmacokinetics

Indexed keywords

CEFEPIME; CREATININE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BARIATRIC SURGERY; BODY MASS; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORBID OBESITY; PRIORITY JOURNAL; PROTEIN BINDING; WEIGHT REDUCTION;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; SURGICAL WOUND INFECTION; TREATMENT OUTCOME;

EID: 84857363851     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-011-0586-8     Document Type: Article

References (46)

1. World Health Organization. Obesity and overweight. Fact sheet 311. September 2006.
2. PS Choban R Heckler JC Burge, et al. 1995 Increased incidence of nosocomial infections in obese surgical patients Am Surg 61 1001 1005 7486411 1:STN:280:DyaK28%2FivFGltg%3D%3D (Pubitemid 26166662)
3. Z Canturk NZ Canturk B Cetinarslan, et al. 2003 Nosocomial infections and obesity in surgical patients Obes Res 11 769 775 12805398 10.1038/oby.2003.107 (Pubitemid 41151603)
4. PS Barie SR Eachempati 2005 Surgical site infections Surg Clin North Am 85 1115 1135 16326197 10.1016/j.suc.2005.09.006 (Pubitemid 41744032)
5. OA Bamgbade TW Rutter OO Nafiu, et al. 2007 Postoperative complications in obese and nonobese patients World J Surg 31 556 560 16957821 10.1007/s00268-006-0305-0 (Pubitemid 46356076)
6. SA Nasraway Jr M Albert AM Donnelly, et al. 2005 Morbid obesity is an independent determinant of death among surgical critically ill patients Crit Care Med 34 964 970 10.1097/01.CCM.0000205758.18891.70
7. D Dindo MK Muller M Weber, et al. 2003 Obesity in general elective surgery Lancet 361 2032 2035 12814714 10.1016/S0140-6736(03)13640-9 (Pubitemid 36695045)
8. JA Greenberg MK Robinson 2009 Surgery: how safe is bariatric surgery? Nat Rev Endocrinol 5 645 646 19924147 10.1038/nrendo.2009.221
9. MA Olsen JJ Nepple KD Riew, et al. 2008 Risk factors for surgical site infection following orthopaedic spinal operations J Bone Joint Surg Am 90 62 69 18171958 10.2106/JBJS.F.01515
10. EL Gillespie JL Kuti DP Nicolau 2005 Pharmacodynamics of antimicrobials: treatment optimization Expert Opin Drug Metab Toxicol 1 351 361 16863448 10.1517/17425255.1.3.351 1:CAS:528:DC%2BD2MXhtVGjsLrF
11. CE Edmiston Jr C Krepel H Kelly, et al. 2004 Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels? Surgery 136 738 747 15467657 10.1016/j.surg.2004.06.022 (Pubitemid 39311298)
12. DE Salazar GB Corcoran 1988 Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass Am J Med 84 1053 1060 3376975 10.1016/0002-9343(88)90310-5 1:STN:280:DyaL1c3jvVKjug%3D%3D
13. FM Pieracci PS Barie A Pomp 2006 Critical care of the bariatric patient Crit Care Med 34 1796 1804 16607234 10.1097/01.CCM.0000217216.84983.0A (Pubitemid 43810065)
14. K Chiba M Tsuchiya J Kato, et al. 1989 Cefotiam disposition in markedly obese athlete patients, Japanese sumo wrestlers Antimicrob Agents Chemother 33 1188 1192 2802548 1:STN:280:DyaK3c%2FisV2kug%3D%3D (Pubitemid 19191954)
15. RL Yost H Derendorf 1986 Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects Ther Drug Monit 8 189 194 3726933 10.1097/00007691-198606000-00011 1:CAS:528:DyaL28Xlt1Krsr8%3D (Pubitemid 16084176)
16. MP Pai DT Bearden 2007 Antimicrobial dosing considerations in obese adult patients Pharmacother 27 1081 1091 10.1592/phco.27.8.1081 1:CAS:528: DC%2BD2sXptlKqtL4%3D (Pubitemid 47173654)
17. DT Bearden KA Rodvold 2000 Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics Clin Pharmacokinet 38 415 426 10843460 10.2165/00003088-200038050-00003 1:CAS:528:DC%2BD3cXktFGqsLc%3D (Pubitemid 30265261)
18. WA Craig 1995 Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins Diagn Microbiol Infect Dis 22 89 96 7587056 10.1016/0732-8893(95) 00053-D 1:CAS:528:DyaK2MXntlGqurk%3D
19. DS Burgess RW Hastings TC Hardin 2000 Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion Clin Ther 22 66 75 10688391 10.1016/S0149-2918(00)87978-3 1:CAS:528:DC%2BD3cXhsVaqtLo%3D (Pubitemid 30091424)
20. ED Hermsen M Maiefski MC Florescu, et al. 2009 Comparison of the modification of diet in renal disease and Cockcroft-Gault equations for dosing antimicrobials Pharmacotherapy 29 649 655 19476418 10.1592/phco.29.6.649 1:CAS:528:DC%2BD1MXhtVGitr%2FN
21. NT Nguyen G Dakin B Needleman, et al. 2010 Effect of staple height on gastrojejunostomy during laparoscopic gastric bypass: a multicenter prospective randomized trial Surg Obes Relat Dis 6 477 482 20870179 10.1016/j.soard.2010.03. 294
22. S Topaloglu FM Avsar H Ozel, et al. 2005 Comparison of bariatric and non-bariatric elective operations in morbidly obese patients on the basis of wound infection Obes Surg 15 1271 1276 16259885 10.1381/096089205774512465 (Pubitemid 41565124)
23. Hospital-Acquired Conditions. [Website]: Centers for Medicare & Medicaid Services, 7500 Security Boulevard Baltimore, MD; 2010 [cited 2010 March 15]; Hospital-Acquired Conditions]. Available from: http://www.cms.hhs.gov/ HospitalAcqCond/06-Hospital-Acquired-Conditions.asp.
24. T Chopra JJ Zhao G Alangaden, et al. 2010 Preventing surgical site infections after bariatric surgery: value of perioperative antibiotic regimens Expert Rev Pharmacoecon Outcomes Res 10 317 328 20545596 10.1586/erp.10.26
25. R Gonzalez MG Sarr CD Smith, et al. 2007 Diagnosis and contemporary management of anastomotic leaks after gastric bypass for obesity J Am Coll Surg 204 47 55 17189112 10.1016/j.jamcollsurg.2006.09.023 (Pubitemid 44960043)
26. N Kermarrec JP Marmuse J Faivre, et al. 2008 High mortality rate for patients requiring intensive care after surgical revision following bariatric surgery Obes Surg 18 171 178 18175195 10.1007/s11695-007-9301-1
27. S Patel S Szomstein RJ Rosenthal 2011 Reasons and outcomes of reoperative bariatric surgery for failed and complicated procedures (excluding adjustable gastric banding) Obes Surg 21 1209 1219 20676940 10.1007/s11695-010-0234-8
28. L Angrisani F Furbetta SB Doldi, et al. 2003 Lap band adjustable gastric banding system: the Italian experience with 1863 patients operating on 6 years Surg Endosc 17 409 412 12457216 10.1007/s00464-002-8836-4 1:STN:280: DC%2BD3s7gs1ehuw%3D%3D (Pubitemid 36302319)
29. N Bercault T Boulain K Kuteifan, et al. 2004 Obesity-related excess mortality rate in an adult intensive care unit: a risk-adjusted matched cohort study Crit Care Med 32 998 1003 15071392 10.1097/01.CCM.0000119422.93413.08 (Pubitemid 38471522)
30. DE Fry 1996 The importance of antibiotic pharmacokinetics in critical illness Am J Surg 172 20S 25S 9003686 10.1016/S0002-9610(96)00346-7 1:CAS:528:DyaK2sXhtV2iu7g%3D (Pubitemid 27056955)
31. HJ Mann H Buchwald 1986 Cefamandole distribution in serum, adipose tissue, and wound drainage in morbidly obese patients Drug Intell Clin Pharm 20 869 873 3780419 1:STN:280:DyaL2s%2FltlejtQ%3D%3D (Pubitemid 16010361)
32. RH Barbhaiya ST Forgue CR Gleason, et al. 1992 Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects Antimicrob Agents Chemother 36 552 557 1622165 1:CAS:528: DyaK38XhvVOntrY%3D
33. M Chen AN Nafziger GL Drusano, et al. 2006 Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal weight, obese, and extremely obese adults Antimicrob Agents Chemother 50 1222 1227 16569832 10.1128/AAC.50.4.1222-1227.2006 1:CAS:528:DC%2BD28XjvFOku74%3D
34. JT Freeman DJ Anderson MG Hartwig, et al. 2010 Surgical site infections following bariatric surgery in community hospitals: a weighty concern? Obes Surg 21 7 836 840 10.1007/s11695-010-0105-3
35. Ho VP, Nicolau DP, Dakin GF, et al. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect (Larchmt). 2012 (in press).
36. AH Mutnick PR Rhomberg HS Sader, et al. 2004 Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001) J Antimicrob Chemother 53 290 296 14711839 10.1093/jac/dkh039 1:CAS:528:DC%2BD2cXos1aqsQ%3D%3D (Pubitemid 38239964)
37. US Food and Drug Administration. Maxipime (cefepime hydrochloride) for injection. NDA 50-679/S021. http://www.fda.gov/medwatch/SAFETY/2003/03MAR-PI/ Maxipime-PI.pdf.
38. S Alfandari C Bonenfant L Depretere, et al. 2007 Use of 27 parenteral antimicrobial agents in north of France hospitals Med Mal Infect 37 103 107 17303361 10.1016/j.medmal.2006.10.010 1:STN:280:DC%2BD2s7kvVOrsA%3D%3D (Pubitemid 46357587)
39. HS Sader TR Fritsche RN Jones 2005 Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003) Siagn Microbiol Infect Dis 52 265 273 10.1016/j. diagmicrobio.2005.02.003 (Pubitemid 41133554)
40. FW Goldstein 2002 Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation Clin Microbiol Infect 8 823 825 12519358 10.1046/j.1469-0691.2002.00492.x 1:STN:280:DC%2BD3s%2Fhtlejug%3D%3D (Pubitemid 36054287)
41. WE Sanders Jr JH Tenney RE Kessler 1996 Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species Clin Infect Dis 23 454 461 8879764 10.1093/clinids/23.3.454 1:CAS:528: DyaK28XlvVGgtb0%3D (Pubitemid 26304490)
42. D Yahav M Paul A Fraser, et al. 2007 Efficacy and safety of cefepime: a systematic review and meta-analysis Lancet Infect Dis 7 338 348 17448937 10.1016/S1473-3099(07)70109-3 1:CAS:528:DC%2BD2sXlslWgt7k%3D (Pubitemid 46591956)
43. PS Barie LJ Hydo DH Larone, et al. 2005 Influence of antibiotic therapy on mortality of critical surgical illness caused or complicated by infection Surg Infect (Larchmt) 6 41 54 10.1089/sur.2005.6.41 (Pubitemid 40711364)
44. WA Craig 1998 Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1 10 9455502 10.1086/516284 1:CAS:528:DyaK1cXltVaqtw%3D%3D
45. JL Crandon CC Bulik JL Kuti, et al. 2010 Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa Antimicrob Agents Chemother 54 1111 1116 20038614 10.1128/AAC.01183-09 1:CAS:528: DC%2BC3cXjtFWqs7Y%3D
46. B Georges JM Conil P Cougot, et al. 2005 Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen Int J Clin Pharmacol Ther 43 360 369 16119511 1:CAS:528:DC%2BD2MXpsFGksrc%3D (Pubitemid 41078996)